by GlyTherix | Oct 18, 2024
We are pleased to announce GlyTherix is presenting an e-poster titled “Determination of Optimal Imaging Dose of [89Zr]Zr-DFO-Miltuximab and Maximum Tolerated Therapeutic Dose of [177Lu]Lu-DOTA-Miltuximab.” This will showcase our groundbreaking research in...
by GlyTherix | Oct 8, 2024
Exciting News in Targeted Radiotherapy! GlyTherix Ltd has signed a global clinical supply agreement with Eckert & Ziegler, a leader in isotopes for nuclear medicine. This collaboration will provide GMP-grade Lutetium-177 chloride for GlyTherix’s clinical...
by GlyTherix | Sep 18, 2024
GlyTherix is pleased to announce a new global clinical supply agreement with Wisconsin-based SHINE Technologies, a pioneer in next-generation fusion-based technology and North America’s largest producer of non-carrier added lutetium-177 (n.c.a. Lu-177) chloride....
by GlyTherix | Sep 10, 2024
GlyTherix Ltd is pleased to announce the execution of a Master Service Agreement with 3D Imaging LLC (3DI), a Contract Development and Manufacturing Organization (CDMO), for the manufacture of GlyTherix’s targeted radiotherapy antibody products for its US clinical...
by GlyTherix | Aug 29, 2024
GlyTherix is thrilled to be invited to speak at the AusBiotech 2024 National Conference. In a session titled “The rise of radiopharmaceuticals: How Australian biotech is at the forefront of this resurgence” GlyTherix CEO, Dr Brad Walsh will be presenting with other...
by GlyTherix | Jul 11, 2024
We are pleased to work with the Cyclowest team, Nat Lenzo and Thomas Tuchyna to bring new targeted radiotherapies to patients. Cyclowest started to produce Zirconium-89 with a plan to obtain TGA licensing for several Zr-89 products over the next 12 months. GlyTherix...
